MAPT and Alzheimer disease: The study revealed that AD biomarkers diverged in a sequential pattern years before diagnosis: CSF Aβ42 levels at 18 years, Aβ42/Aβ40 at 14 years, p‐tau at 11 years, total tau at 10 years, NfL at 9 years, and hippocampal volume loss at 8 years.